Comorbidities as a Personalized Target in Patients with Severe Asthma Treated with Dupilumab
Open Access
- 2 October 2025
- journal article
- research article
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 15 (10) , 471
Abstract
Background: This study aimed to evaluate the clinical effectiveness of dupilumab and its impact on CRSwNP and type 2 inflammatory biomarkers in patients with severe uncontrolled asthma, with or without comorbidities, within a real-life cohort. Methods: This was a single-center, prospective, and observational real-life study conducted at the Severe Asthma Unit of Germans Trias i Pujol University Hospital. The objective of this study was to assess the real-world response to dupilumab treatment in patients with severe asthma, with or without nasal polyposis, bronchiectasis, obesity, or switching from another biologic drug for their asthma. Results: The ACT score significantly increased (13.7 vs. 20.6; p = 0.001), while the number of exacerbations decreased (3.1 vs. 0.7; p = 0.005). Patients with CRSwNP showed an increase in the ACT score (13.1 vs. 19.8; p = 0.011) and a decrease in the number of exacerbations (3.0 vs. 1.3; p = 0.217). Patients with nasal polyps showed an increase in both SNOT22 (78.3 vs. 38.3; p = 0.013) and global VAS (8 vs. 4.2; p = 0.028). Patients with bronchiectasis receiving dupilumab showed an increase in the ACT score (12.7 vs. 21.3; p = 0.039) and a marked decrease in the number of exacerbations (2.8 vs. 0; p = 0.025). Obese patients treated with dupilumab showed an improvement in the ACT score (14.1 vs. 21.3; p = 0.044) and a decrease in the rate of exacerbations (3.2 vs. 1.3; p = 0.030). Patients with rhinoconjunctivitis receiving dupilumab showed an increase in the ACT score (13.4 vs. 19.1; p = 0.017) and a decrease in the number of exacerbations (3.3 vs. 0.8; p = 0.024). Conclusions: Dupilumab is a highly effective treatment for severe asthma, showing significant improvements in lung function, reductions in exacerbations, and enhanced quality of life for patients with and without nasal polyps. The results of this real-life study support dupilumab as a valuable addition to the therapeutic armamentarium for asthma, particularly for those with type 2 inflammation despite the presence of comorbidities such as bronchiectasis or obesity, or for patients in whom a previous biologic treatment failed.Keywords
This publication has 23 references indexed in Scilit:
- Evaluating the Utility of Biologic Therapies in Patients With Severe Asthma and Comorbid Bronchiectasis: A Systematic Review With Meta-analysis of Retrospective StudiesArchivos de Bronconeumología, 2025
- Efficacy of dupilumab for severe chronic rhinosinusitis with nasal polyps and asthmaAnnals of Allergy, Asthma & Immunology, 2024
- Anti–IL-4R versus anti–IL-5/5R after anti–IL-5/5R failure in asthma: An emulated target trialJournal of Allergy and Clinical Immunology, 2024
- Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNPEuropean Archives of Oto-Rhino-Laryngology, 2024
- Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experienceAmerican Journal of Otolaryngology, 2023
- Analysis of comorbidities and multimorbidity in adult patients in the International Severe Asthma RegistryAnnals of Allergy, Asthma & Immunology, 2023
- Efficacy and safety of dupilumab as add-on therapy for patients with severe asthma: A real-world Dutch cohort studyRespiratory Medicine, 2022
- Real‐life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNPClinical and Translational Allergy, 2021
- Chronic Rhinosinusitis with Nasal Polyps and AsthmaThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitisAnnals of Allergy, Asthma & Immunology, 2020